Company intelligence / Profile preview

InhaTarget Therapeutics

Ownership: Private
Development stage: Other

Overview

InhaTarget Therapeutics has developed two anticancer dry powder inhalers currently at the in vivo proof-of-concept stage. The company aims to bridge the gap between localized treatments like surgery/radiotherapy and systemic therapies by delivering drugs directly to lung tumors via targeted inhalation. No clinical trial results have been published yet.

Therapeutic areas: PulmonologyOncology
Modalities: Small moleculeDry powder inhaler (DPI) formulations
Industry: Biotech

Drug pipeline

5 assets

CIS-DPI

4 more assets in the full pipeline.

Partnerships

No major pharma partnerships publicly disclosed; investors include SMB Lab, Galephar Pharmaceutical Research, Sambrinvest, Seido Capital.

Beyond the preview

Go deeper on InhaTarget Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InhaTarget Therapeutics.